The Filing Desk

Evolus vs Xeris Biopharma

Evolus EOLS · Xeris Biopharma XERS · Pharmaceuticals

Evolus reported revenue of $297 million in fiscal 2025, about the same as Xeris Biopharma's $292 million in fiscal 2025. Evolus' revenue grew 11.6% in its latest year, and Xeris Biopharma's grew 43.7%. Evolus had an operating margin of -11.0%, against 8.5% at Xeris Biopharma.

Side by side

EvolusXeris Biopharma
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$297M$292M
Revenue growth11.6%43.7%
Revenue growth a year, last 5 years39.4%70.3%
Gross margin66.3%—
Operating margin−11.0%8.5%
Net margin−17.4%0.2%
Free cash flow−$46M—
Free cash flow margin−15.4%—
Return on capital−47.2%19.6%
Net debt to EBITDA—4.2x
Dividends and buybacks$0M$0M
Change in diluted share count4.0%17.7%
Last close$6.96$16.66
P/E at the last close——
Insider trades, last 12 months—sold $4.7 million
Piotroski F-score2 of 97 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
EvolusXeris Biopharma
Operating margin
Percent of revenue
EvolusXeris Biopharma
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
EvolusXeris Biopharma

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Evolus and Xeris Biopharma pages.